+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Recent developments on coronavirus main protease/3C like protease inhibitors



Recent developments on coronavirus main protease/3C like protease inhibitors



Recent Patents on Anti-Infective Drug Discovery 8(2): 150-156



Coronaviruses have been thrust into the spotlight by the recurring novel human coronavirus infections following the 2003 SARS pandemic. In the years since the initial SARS outbreak, the arsenal to fight this virus family has been significantly increased by the rapid growth of coronavirus research. Among the potential viral drug targets, coronavirus 3C like proteases (3Cl) have emerged as the most popular drug target. A number of patented inhibitors with promising clinical potential have been developed via different methods of drug discovery, including virtual screening, natural product isolation and structure assisted rational drug design. This review serves as a summary of the progress in both the method of drug discovery and the related inhibitors against the coronavirus 3Cl protease.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055400980

Download citation: RISBibTeXText

PMID: 23879823


Related references

Recent Developments on Coronavirus Main Protease/3C Like Protease Inhibitors. 2013

Recent Developments on Coronavirus Main Protease/3C Like Protease Inhibitors. 2013

Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 43(17): 4906-4912, 2004

Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro). Chemical Biology and Drug Design 72(1): 34-49, 2008

Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antiviral Research 92(2): 204-212, 2011

Substrate specificity and rational design of peptidomimetic inhibitors for SARS coronavirus main protease. Hong Kong Medical Journal 20(Suppl. 4): 18-21, 2014

Recent Developments of Peptidomimetic Hiv-1 Protease Inhibitors. Current Medicinal Chemistry 18(29): 4513-4537, 2011

Recent developments of peptidomimetic HIV-1 protease inhibitors. Current Medicinal Chemistry 18(29): 4513-4537, 2011

Human rhinovirus 3C protease inhibitors: recent developments. Expert Opinion on Therapeutic Patents 8(9): 1151-1156, 1998

Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. Journal of Medicinal Chemistry 49(17): 5154-5161, 2006

Double-headed protease inhibitors from black-eyed peas. I. Purification of two new protease inhibitors and the endogenous protease by affinity chromatography. Journal of Biological Chemistry 251(3): 734-740, 1976

A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods. Journal of Medicinal Chemistry 48(22): 6832-6842, 2005

Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Biochemical Society Transactions 39(5): 1371-1375, 2011

Recent developments in the discovery of hepatitis C virus serine protease inhibitors--towards a new class of antiviral agents?. Expert Opinion on Investigational Drugs 12(2): 153-163, 2003

An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors. Chembiochem 7(7): 1048-1055, 2006